Bimatoprost / working resource
Observation and follow-up journal
Record what changed, when it changed and what else could explain it.
Start with the product-specific question
What the label says it is for
Bimatoprost for short or sparse eyelashes, with the evidence and its limits in plain view. What should I know about what the label says bimatoprost is for?
Open the Bimatoprost library ↗In a 2012 randomized trial, subjects were randomized over 5 months to once-daily bimatoprost 0.03% (n = 137) or vehicle (n = 141). A higher percentage of subjects treated with bimatoprost 0.03% (78.1%) than vehicle (18.4%) demonstrated at least a 1-grade increase in global eyelash assessment score at week 16 (P < .0001). The abstract lists the short-term duration of the trial and that black subjects were not enrolled secondary to technical requirements of digital image analysis as limitations.
Read the original record ↗
Describe an observation without assuming a cause.
When researching Bimatoprost, stories about improvement can leave out other changes, time trends and ordinary variation. A clear record preserves those details. Use any monitoring plan agreed with your clinician; this blank journal does not supply one.
Entry 1
Entry 2
Entry 3
Entry 4
Review the record with context.
A personal timeline cannot establish that a product caused a benefit or harm. Seek appropriate care for concerning symptoms rather than waiting to complete a journal.
These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.